While the meta-analysis increased the statistical power of the analysis, further large-scale, multicenter studies are needed to confirm the clinical utility of GSTP1 hypermethylation as a biomarker for HCC (Anzola et al., 2004). The gene discussed is GSTP1; the disease is hepatocellular carcinoma.